### GOVERNMENT OF THE REPUBLIC OF THE UNION OF MYANMAR MINISTRY OF HEALTH AND SPORTS DEPARTMENT OF MEDICAL SERVICES



Clinical Management Guidelines for COVID-19 Acute Respiratory Disease

Version - DoMS/COVID-19/clinical/Version 05-2020

Date - 13<sup>th</sup> April 2020

Clinical Management Guidelines for Corona Virus Disease (COVID-19) Version (5/2020) (updated as of 13<sup>th</sup> April 2020) Department of Medical Services

#### Surveillance case definitions for COVID-19

#### **Suspect case**

 A patient with acute respiratory illness (fever and at least one sign/symptom of respiratory disease (e.g., cough, shortness breath),

#### AND

a history of travel to or residence in a location reporting community transmission of COVID-19 disease during the 14 days prior to symptom onset.

#### OR

2) A patient with any acute respiratory illness

#### AND

having been in *contact* with a confirmed or probable COVID-19 case in the last 14 days prior to onset of symptoms

#### OR

**3**) A patient with severe acute respiratory infection (fever and at least one sign/symptom of respiratory disease, e.g., cough, shortness breath; requiring hospitalization)

#### AND

in the absence of an alternative diagnosis that fully explains the clinical presentation

## \*Note: "Reporting community transmission of COVID-19 disease" should be checked in WHO updated situation report

#### **Probable case**

A. A suspect case for whom testing for the COVID-19 virus is inconclusive.

a. Inconclusive being the result of the test reported by the laboratory.

#### OR

B. A suspect case for whom testing could not be performed for any reason.

#### **Confirmed case**

A person with laboratory confirmation of COVID-19 infection, irrespective of clinical signs and symptoms.

\*see https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/ laboratory-guidance for latest case definitions

#### Criteria for severe acute respiratory infection requiring hospital admission

Anyone of the following parameters:

- Respiratory rate > 30 breaths/min
- Severe respiratory distress
- SpO2  $\leq$  93% on room air
- Systolic blood pressure  $\leq 100 \text{ mmHg}$
- Altered mental status (GCS < 15)

#### **Definition of contact**

A contact is a person who experienced any one of the following exposures during the 2 days before and the 14 days after the onset of symptoms of a probable or confirmed case :

- Face-to-face contact with a probable or confirmed case within 1 meter and for more than 15 minutes;
- Direct physical contact with a probable or confirmed case;
- Direct care for a patient with probable or confirmed COVID-19 disease without using proper personal protective equipment;

(For asymptomatic cases, the period of contact is measured as the 2 days before through the 14 days after the date on which the sample was taken which led to confirmation)

#### Monitoring of contacts of probable and confirmed cases:

- Contacts should be monitored for 21 days from the last unprotected contact.
- All contacts should be kept in facility quarantine arranged by government.
- Any contact of confirmed cases should be tested.
- Any newly identified probable or confirmed cases should have their own contacts identified and monitored

### I. History taking


Name:	Age:	
Sex:	R/N:	
Address:		
Detail of Travel History		
Contact History		

### Complaints

Fever	.Cough	Sore throat	.Headache	Muscle pain	Shortness of
breath	Diarrhoea	Reduced	urine output of	etc	

### II. Physical Examination

Vital signs: GC	S:	Temperature	Cyanosis	BP:
HR:	SpO <sub>2</sub> :	RR:	Lungs:	
Features of Sept	tic shock, Acu	ıte kidney injury		



#### **III.** Categorization of Patients

#### Mild illness

Patients uncomplicated upper respiratory tract viral infection may have non-specific symptoms such as fever, fatigue, cough (with or without sputum production), anorexia, malaise, muscle pain, sore throat, dyspnea, nasal congestion, or headache. Rarely, patients may also present with diarrhoea, nausea, and vomiting. The elderly and immunosuppressed may present with atypical symptoms.

#### Pneumonia

Adult with pneumonia but no signs of severe pneumonia and no need for supplemental oxygen.

#### Severe pneumonia

Fever or suspected respiratory infection, plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress; or SpO2  $\leq$  93% on room air.

#### Acute Respiratory Distress Syndrome

- New or worsening respiratory symptoms within one week of known clinical insult.
- Bilateral opacities on CXR, not fully explained by effusions, lobar or lung, collapse, or nodules.
- Respiratory failure not fully explained by cardiac failure or fluid overload.

#### Sepsis

- Life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection.
- Signs of organ dysfunction include: altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia.

#### Septic shock

• Patients with persisting hypotension despite volume resuscitation, requiring vasopressors to maintain MAP ≥65 mmHg and serum lactate level >2 mmol/L.

**The SOFA score** ranges from 0 to 24 and includes points related to 6 organ systems: respiratory (hypoxemia defined by low  $PaO_2/FiO_2$ ),

coagulation (low platelets), liver (high bilirubin),

cardiovascular (hypotension),

central nervous system (low level of consciousness defined by Glasgow Coma Scale), renal (low urine output or high creatinine).

Sepsis is defined by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of  $\geq 2$  points. Assume the baseline score is zero if data are not available

#### SOFA Score (Sequential (Sepsis related) Organ Failure Assessment Score)

System or organ and	SOFA scor	e			
measure	0	1	2	3	4
Respiratory:					
$P_aO_2/FiO_2$ , mmHg	≥400	300-399	200-299	100-199 with respiratory support	<100 with respiratory support
Coagulation:					
Platelets, × $10^3/\mu L$	≥150	100-149	50-99	20-49	<20
Liver:					
Bilirubin, µmol/L (mg/dL)	<20 (1.2)	20-32 (1.2-1.9)	33-101 (2.0-5.9)	102-204 (6.0-11.9)	>204 (12.0)
Circulatory:					
Mean arterial pressure, mm Hg	≥70	<70	Low dose dopamine or any dose dobutamine	Low-medium dose noradrenalin or adrenalin; medium dose dopamine	High dose noradrenalin, adrenalin, or dopamine
Central nervous system:					
Glasgow Coma Scale score	15	13-14	10-12	6-9	<6
Renal:					
Creatinine, µmol/L (mg/dL)	<110 (1.2)	110-170 (1.2- 1.9)	171-299 (2.0- 3.4)	300-440 (3.5-4.9)	>440 (5.0)
Urine output, mL/day	_	-	-	<500	<200

\*Our recommendation applies to patients with an infection and a SOFA score of  $\geq 2$ .

 $P_aO_2$  = partial pressure of oxygen (arterial).  $F_iO_2$  = fraction of inspired oxygen.

#### **IV. Investigations**

- Collection of blood cultures (if possible)— for bacteria that cause pneumonia and sepsis, ideally before antimicrobial therapy. Do not delay antimicrobial therapy to collect blood cultures.
- Collection of specimens from the upper respiratory tract (nasopharyngeal and oropharyngeal) AND, where clinical suspicion remains and URT specimens are negative, collect specimens from the lower respiratory tract when readily available (expectorated sputum, endotracheal aspirate, or bronchoalveolar lavage in ventilated patient) for COVID-19 virus testing by RT-PCR and bacterial stains/cultures.
- In hospitalized patients with confirmed COVID-19, repeated URT and LRT samples can be collected to demonstrate viral clearance. The frequency of specimen collection will depend on local epidemic characteristics and resources.
- Detection of malaria parasites by RDT or blood film for patients with fever in malarial endemic areas should be considered.
- Detection of dengue/chikungunya may also be considered in the differential diagnosis of undifferentiated febrile illness, particularly when thrombocytopenia is present.
- CP, ESR, RBS, U&E, Creatinine, LFT with Enzymes,
- If possible CRP, D-Dimer, LDH, ABG,
- ECG, CXR (PA)

#### Recommendations for laboratory testing

- Any suspected case should be tested for COVID-19 infection using available molecular tests.
- Based on clinical judgment, clinicians may opt to order a test for COVID-19 in a
  patient not strictly meeting the case definition, for example, if there are patients
  involved in a cluster of acute respiratory illness among healthcare workers or of
  severe acute respiratory infection (SARI) or pneumonia in families, workplaces or
  social network.
- If clinicians strongly suspect possibility of covid-19 infection, 2<sup>nd</sup> swab should be considered in PUI cases (if 1<sup>st</sup> swab test is negative).

#### V. Treatment

<u>A. Immediate implementation of IPC measures</u> (Should start at the point of entry to hospitals)

#### At triage

- Screening should be done at first point of contact at the emergency department or outpatient department.
- Give suspect patient a medical mask and direct patient to separate area, an isolation room if available.
- Keep at least 1 meter distance between suspected patients and other patients.
- Instruct all patients to cover nose and mouth during coughing or sneezing with tissue or flexed elbow for others.
- Perform hand hygiene after contact with respiratory secretions.

#### Apply standard precaution

- hand hygiene (alcohol based hand rub/water and soap), use of PPE to avoid indirect and direct contact with patients' blood, body fluids, secretions and non-intact skin.
- prevention of needle-stick or sharps injury; safe waste management; cleaning and disinfection of equipment; and cleaning of the environment.

#### Apply droplet precaution

- Use medical mask if working within 1 metre of the patient.
- Use eye protection (face-mask or goggles)
- Limit patient movement within the institution and ensure that patients wear medical masks when outside their rooms.

#### Apply contact precaution

- Use PPE (medical mask, eye protection, gloves and gown) when entering room and remove PPE when leaving.
- If possible, use either disposable or dedicated equipment (e.g. stethoscopes, blood pressure cuffs and thermometers).
- If equipment needs to be shared among patients, clean and disinfect between each patient use.
- Minimal movement of patients or transport as much as possible.

#### Apply air-borne precaution

- Use PPE, including gloves, long-sleeved gowns, eye protection, and fit-tested particulate respirators (N95 or equivalent, or higher level of protection) when healthcare workers performing aerosol-generating procedures (i.e. open suctioning of respiratory tract, intubation, bronchoscopy, cardiopulmonary resuscitation).
- Avoid the presence of unnecessary individuals in the room.
- Care for the patient in the same type of room after mechanical ventilation commences.

#### **B. Management of mild COVID-19**

- Patients with mild disease should be admitted to hospital.
- Isolation can be done in hospital.
- Symptomatic treatment such as antipyretics (paracetamol) for fever.

#### C. Management of severe COVID-19

#### Supplemental oxygen therapy

- For patients with SARI and respiratory distress, hypoxaemia, or shock.
- Target  $SpO_2 \ge 90\%$  in non-pregnant adults and  $SpO_2 \ge 92-95\%$  in pregnant patients.

#### Fluid management

• Use conservative fluid management in patients with SARI when there is no evidence of shock.

\* Patients with SARI should be treated cautiously with intravenous fluids, because

aggressive fluid resuscitation may worsen oxygenation

#### Empirical antimicrobial treatment

- Give antimicrobials within one hour of identification of sepsis.
- Neuraminidase inhibitor when there is local circulation or other risk factors, including travel history or exposure to animal influenza viruses.
- Mild pneumonia PO Augmentin 625 mg tds + PO Azithromycin 500mg od x 5 days
- Severe pneumonia (community acquired)

IV Augmentin 1.2 g 8h (ATD) for 7 days +

IV Azithromycin 500 mg OD for 7 days

Followed by extend or change other antibiotics according to clinical and lab results.

OR

IV Cefoperazone + sulbactam 2g 12hrly **plus** PO Clarithromycin 500mg bd or IV Azithromycin 500mg infusion od x 5 days

• Severe pneumonia (hospital acquired)

IV Cefepime 1g 8h (ATD) + IV Meropenem 1g in N/S 100 ml (ATD) 8h, if needed add IV Moxifloxacin 400mg OD (ATD) for 7-14 days

(Attending physician should modify empirical antibiotic on the basis of microbiology result and clinical judgement)

Closely monitor patients with SARI for signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis, and apply supportive care interventions immediately

Understand the patient's co-morbid condition(s) to tailor the management of critical illness and appreciate the prognosis. Communicate early with patient and family

#### **D.** Treatment of complications

Respiratory Failure & ARDS -	Mechanical ventilation
Septic shock -	Fluid resuscitation with 250–500 mL crystalloid fluid as
	rapid bolus in first 15–30 minutes and reassess for signs
	of fluid overload after each bolus. Administer
	Noradrenalin if shock persists during or after fluid
	resuscitation, consider dobutamine if not responded to
	fluid and noradrenalin, etc.

\* Do not use hypotonic crystalloids, starches, or gelatins for resuscitation. Fluid resuscitation may lead to volume overload, including respiratory failure. If there is no response to fluid loading and signs of volume overload appear (for example, jugular venous distension, crackles on lung auscultation, pulmonary oedema on imaging, or hepatomegaly in children) Administer vasopressors when shock persists during or after fluid resuscitation. Norepinephrine is considered first-line in adult patients

Rate	ml/hr					
	40kg	45kg	50kg	55kg	60 kg	
0.05ug/kg/min	0.6	0.7	0.8	0.8	0.9	
0.1 ug/kg/min	1.2	1.4	1.5	1.7	1.8	
0.15 ug/kg/min	1.8	2	2.3	2.5	2.7	
0.2 ug/kg/min	2.4	2.7	3	3.3	3.6	
0.25 ug/kg/min	3	3.4	3.8	4.1	4.5	

#### **Noradernaline Infusion**

#### **E. Prevention of complications**

- For prophylaxis of venous-thromboembolism, consider LMWH (low molecularweight heparin) OD or unfractionated heparin 5000 units subcutaneously twice daily) in adolescents and adults without contraindications. For those with contraindications, use mechanical prophylaxis (intermittent pneumatic compression devices).
- Turn patient every two hours
- Awake proning position may reduce ICU admission (see attached photo)
- Give early enteral nutrition (within 24–48 hours of admission)
- Administer H<sub>2</sub> blockers or PPI in patients with risk factors for GI bleeding.
- Actively mobilize the patient early in the course of illness when safe to do so

#### F. Therapeutic Option for COVID-19 Disease

# *This option is needed to consult with central level clinical management committee before starting it.*

- For patients with confirmed COVID-19 Disease (mild, moderate and severe disease), start hydroxychloroquine (HCQ) if there are no contraindications.
  - 400 mg BD for 1 day followed by
  - 200 mg BD for 4 days

#### Contra-indications to HCQ

- QTc > 500 msec
- drug interaction

- Myasthenia gravis
- Porphyria
- Retinal pathology
- Epilepsy
- ➢ For patients with confirmed COVID-19 Critical disease (≥ 1 of the following: □ Acute Respiratory Distress Syndrome □ Sepsis □ Altered consciousness □ Multiorgan failure), start hydroxychloroquine, crushed in nasogastric tube at the same dosage and monitor as above.

#### Important side effects of HCQ

- Prolonged QT interval
- ➢ Haemolysis with G6PD deficiency
- Retinopathy with retinal pigmentation changes

#### Alternative therapy

If HCQ is not available, consider

- Chloroquine base 600mg (4 tabs) stat,
- 300mg (2 tabs) after 12h , followed by
- 300mg (2 tabs) BD for 4 days

#### Note:

- \*\*Pregnancy is not a contraindication as such. Perform basic biochemistry daily and ECG daily if initial QTc > 450 msec. Avoid quinolones if possible, or monitor closely the QT if these antibiotics are needed.
- \*\*Attending physician decision should be taken into account for use of HCQ.
- \*\*Caution is required in cardiac, liver and renal failure when using HCQ.
- \*\*Counseling should be done before administering Hydroxychloroquine or Chloroquine to patients and consent should be taken.
- \*\*Patients should be monitored for side effects and to give appropriate prompt action if present.

#### **G. Adjunctive therapies for COVID-19: corticosteroids**

• IV Methylprednisolone 40mg 12 hrly for 5 days (1-2mg/kg/day), if indicated e.g. severe pneumonia.

#### **<u>H. Treatment of pregnant patients</u>**

- Considering asymptomatic transmission of COVID-19 may be possible in pregnant or recently pregnant women, all women with epidemiologic history of contact should be carefully monitored.
- Pregnant women with suspected, probable, or confirmed COVID-19 should have access to woman-centred, respectful skilled care, including obstetric, fetal medicine and neonatal care, as well as mental health and psychosocial support, with readiness to care for maternal and neonatal complications.
- Pregnant and recently pregnant women who have recovered from COVID-19 should be enabled and encouraged to attend routine antenatal, postpartum, or postabortion care as appropriate. counselling on safe infant feeding and appropriate IPC measures to prevent COVID-19 virus transmission should also be done.
- Emergency delivery and pregnancy termination decisions are challenging and based on many factors: gestational age, maternal condition, and fetal stability.
- Consultations with obstetric, neonatal, and intensive care specialists (depending on the condition of the mother) are essential.

#### I. Monitoring

• Signs of clinical deterioration, such as rapidly progressive respiratory failure and sepsis and respond immediately with supportive care interventions.

#### J. Management of critical COVID-19: acute respiratory distress syndrome (ARDS)

#### ICU Management Guideline

#### Criteria for ICU Admission (If any of one)

- 1. Respiratory rate  $\geq 30/\text{min}$
- SpO2 <90% with standard Oxygen Therapy (face mask with reservoir bag 10-15 L/min)</li>
- 3. SpO2/FiO2 < 315
- 4. PaO2/FiO2 < 200 (If ABG available) (Moderate ARDS)
- 5. Severe pneumonia with sepsis/ septic shock

Closed observation and monitoring, optimization of oxygenation to maintain SpO2 > 90%

# Criteria for endotracheal intubation should be based on individual situation. The followings are red signs;

- 1. Respiratory rate > 35/min, severe respiratory distress with increased work of breathing
- 2. PaO2/FiO2 < 200 (If ABG available) or SpO2/FiO2 <150
- 3. Severe acidosis pH <7.25 (If ABG available)
- 4. Altered mental status
- 5. Haemodynamic instability (MAP  $\leq 65$  mmHg) after fluid resuscitation and vasopressor/inotrope support) (according to updated SSC guideline Hour 1 bundle)

## Endotracheal intubation must be followed the COVID-19 Airway management principles, WFSA guideline.

Endotracheal intubation should be performed by a trained and experienced provider using airborne precautions.

Remarks: Patients with ARDS, especially young children or those who are obese or pregnant, may desaturate quickly during intubation. Pre-oxygenate with 100% FiO2 for 5 minutes. Rapid sequence intubation is appropriate after an airway assessment.

#### VENTILATOR SETUP AND ADJUSTMENT

- 1. Calculate predicted body weight (PBW)
  - a. Males = 50 + 2.3 [height (inches) 60]
  - b. Females = 45.5 + 2.3 [height (inches) -60]
- 2. Select any ventilator mode, AC or SIMV mode
- **3.** Initial tidal volume is 6 ml/kg PBW; tidal volume up to 8 ml/kg PBW
- 4. Set initial rate to approximate baseline minute ventilation (not > 35 bpm).
- 5. Adjust PEEP (5-15) and FiO2 to achieve SpO2 88-92% (PaO2- 55-80 mmHg) lower inspiratory pressures (plateau pressure <30 cmH2O).
- 6. The use of deep sedation may be required to control respiratory drive and to reduce the patient-ventilator dys-synchrony.
- 7. Use a conservative fluid management strategy for ARDS patients without tissue hypoperfusion.
- 8. In patients with moderate-severe ARDS (PaO2/FiO2 <150), neuromuscular blockade by continuous infusion should not be routinely used.

#### **Discharge Criteria**

#### For PUI case came out COVID-19 negative result from Swab

- 1) Move from isolation ward to cohort room (so call room to meet others plan for DC)
- 2) Need to explore DC parade and counseling in 2 days stay in cohort room.
- Afebrile and resolving respiratory symptoms for at least 48 hours, and, stable on comorbid conditions for at least 48 hours (if co-morbid condition is not stable, refer to appropriate specialist for consultation)
- 4) Follow-up on 2 weeks after discharge (if anything happens, return to hospital anytime)

#### **Discharge Criteria for confirmed COVID-19 patients**


#### **Confirmed COVID-19 Cases**


- 1. Afebrile for at least 48 hours
- 2. Resolving respiratory symptoms
- 3. Improving radiological signs
- 4. Improved well-being
- 5. Having had at least 2 consecutive, 48-hours apart, tests negative results of nasopharyngeal or oropharyngeal swab
- 6. Testing of nasopharyngeal or oropharyngeal swabs:
  - a. Conduct the test on day 11: if negative the next test will be conducted on day 13 and if negative, discharge on day 14. After discharge, transfer the patient to ensure stay of 7 more days in facility isolation, and then 7 more days in home isolation.
  - b. If positive on day 11: conduct another test after 6 days, and repeat after 6 more days until the test becomes negative, e.g. day 11, day 17, day 23, day 29, etc. When test becomes negative one more test will be conducted 48 hours later. If negative again, discharge on the next day. Manage as appropriate to have a total of 28 days in isolation.
- NB: In any case, confirmed COVID-19 patients should be kept in a hospital isolation for at least 14 days.

#### COVID-19 Airway management principles according to WFSA guideline

# High Risk Procedures – Tracheal Intubation and other Aerosol-generating medical procedures

- Limit staff present at tracheal intubation: one intubator, one assistant and one to administer drugs/monitor patient.
- Preferably, the most experienced anaesthesiologist should perform the intubation.
- Create a COVID-19 tracheal intubation trolley that can be used in ICU or elsewhere.
- PPE is effective and must be worn. Wear full PPE at all times. Consider double gloving. Defog goggles and/or eye wear if possible. Touch as little as possible in the room to avoid fomites.
- Everyone should know the plan before entering the room use a checklist to achieve this.
- Plan how to communicate before entering the room.
- All preparations of airway equipment and drugs that can take place outside the room should do.
- Before the procedure begins, ensure all equipment is ready: standard monitoring equipment, iv access, drugs. Ensure ventilator and suction equipment is functional.
- Focus on safety, promptness and reliability. Aim to succeed at the first attempt because multiple attempts increase risk to sick patients and staff. Do not rush but make each attempt the best it can be.
- Place an HME with viral filter between the catheter mount and the circuit at all times. Keep it dry to avoid blocking.
- Avoid aerosol-generating procedure, including high-flow nasal oxygen, non-invasive ventilation, bronchoscopy and tracheal suction unless an in-line suction system is in place.
- Use RSI with cricoid force where a trained assistant can apply it. Take it off if it causes difficulty. Five minutes of preoxygenation with oxygen 100% and RSI in order to avoid manual ventilation and potential aerosolization of infectious respiratory droplets. If manual ventilation is required, apply small tidal volumes only.
- To avoid cardiovascular collapse, use ketamine 1–2 mg.kg<sup>-1</sup>, suxamethonium 1.5 mg.kg<sup>-1</sup>.
- Have a vasopressor for bolus or infusion (noradrenalin 0.05-1 µg/kg/min) immediately available for managing hypotension.
- Communicate clearly: simple instructions, closed loop communication (repeat instructions back), adequate volume without shouting.
- Place a nasogastric tube after tracheal intubation is completed and ventilation established safely.
- Discard disposable equipment safely after use. Decontaminate reusable equipment fully and according to manufacturer's instructions.
- After leaving the room ensure doffing of PPE is meticulous.





#### **Rational use of PPE**

ပူးတွဲ 'ခ'

အကြောင်းအရာ	Medical Mask	N95 mask	Gown	Gloves	Eyes protection (Goggles or face shield)	Boots/ closed shoes
ပြင်ပလူနာ ဌာန၌ Screening ပြုလုပ်ခြင်း	(+) အသက်ရှူလမ်းကြောင်း ဆိုင်ရာ လက္ခဏာများ (Respiratory symptoms) ရှိသူတိုင်း အတွက် အသုံးပြုရန်	(-)	(-)	(-)	(-)	(-)
လူနာများအား သံသယရှိပါက သီးခြား စမ်းသပ်ခန်း (Fever room/ Temporary isolation room) ၌ စမ်းသပ်ခြင်း	(+)	(-)	(+)	(+)	(-)	(-)
သံသယလူနာများ (Person under investigation/ suspected) လူနာခန်း၌ စမ်းသပ်ခြင်း/ ကုသခြင်း	(+)	(-)	(+)	(+)	(+)	(-)
ဓာတ်ခွဲစစ်ဆေးမှုပြုလုပ်သူများ/ Sample ယူခြင်း	(-)	(+)	(+)	(+)	(+)	(-)
Aerosol-generating procedures များ (e.g; tracheal incubation, non-invasive ventilation, tracheostomy, cardio pulmonary resuscitation, manual ventilation, bronchoscopy) ပြုလုပ်ခြင်း	(-)	(+)	(+) Apron ပါ ဝတ်ဆင်ရန်	(+)	(+)	(-)
လူနာများအား လူနာတင်ယာဉ်ဖြင့် သယ်ဝို့ ရာတွင် အသက်ကယ်ကုသမှု ပြုလုပ်မည့် အထောက်အကူပြု	(+)	(-)	(+)	(+)	(+)	(-)

COVID-19 Acute Respiratory Disease နှင့် ပတ်သက်၍ Personal Protective Equipment ဝတ်ဆင်ရန် လုပ်ငန်းလမ်းညွှန်

၁၅

အကြောင်းအရာ	Medical Mask	N95 mask	Gown	Gloves	Eyes protection (Goggles or face shield)	Boots/ closed shoes
ဝန်ထမ်းများ/ လူနာအား ထိတွေ့ကိုင်တွယ်မည့်သူများ			-			
လူနာခန်းအား သန့်ရှင်းရေးပြုလုပ်သူများ	(+)	(-)	(+)	(+) (Heavy duty gloves)	(+)	(+)
လူနာခန်းသို့ ဝင်ရောက်မည့် ဧည့်သည်များ	(+)	(-)	(+)	(+)	(-)	(-)

Reference : Rational Use of Personal Protective Equipment for Coronavirus Disease 2019 (WHO)

မှတ်ချက်

- ကျန်းမာရေးဝန်ထမ်းများသည် လူနာများအား ထိတွေ့ကိုင်တွယ်ခြင်း မပြုမီ နှင့် ထိတွေ့ကိုင်တွယ်ပြီးနောက် လက်ကို (Alcohol hand sanitizer/ ဆဝ်ပြာနှင့် ရေဆေးခြင်းဖြင့်) စနစ်တကျ ဆေးကြောရမည်။
- သံသယလူနာများအား စမ်းသပ်စစ်ဆေးရန် မလိုအပ်သူသည် (ဥပမာ Screening ပြုလုပ်ခြင်း/မေးမြန်းခြင်း၊ လူနာတင်ယာဉ် ယာဉ်မောင်း) လူနာနှင့် အနည်းဆုံး
   တစ်ခီတာ သို့မဟုတ် သုံးပေ ခွာ၍ သတိပြု နေထိုင်ရပါမည်။
- လူနာများတွင် အသက်ရှူလမ်းကြောင်းဆိုင်ရာ ရောဂါလက္ခဏာများ ရှိပါက လူနာအား Medical Mask တဝိဆင်ပေးရမည်။ အသက်ရှူလမ်းကြောင်းဆိုင်ရာ ရောဂါလက္ခဏာများ မရှိပါက Mask တဝိဆင်ပေးရန် မလိုအဝိပါ။

မလိုအပ်ဘဲ PPE များ အသုံးပြုခြင်းကို တတ်နိုင်သမျှ ရှောင်ကြည်ရပါမည်။

၁၆


#### Awake proning guide

#### Aims

Awake proning **may reduce** ICU admissions. Intubation in COVID19 has a high mortality. Patient **must** be **awake** and willing to **comply**.

#### Duration

Aim to remain prone for **4 hours periods**. Allow **1 hour comfort breaks** between periods of proning for eating, drinking, toilet and general comfort.



#### VII. References:

- World Health Organization, 2014. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: what to do and what not to do. 2013-03-20]. http://www. who. int/csr/disease/coronavirus \_ infections/InterimGuidance \_ ClinicalManagement\_Novel Coronavirus\_l 1Fehl 3 u. pdf. (28 Jan 2020).
- Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected Interim guidance 13 March 2020, WHO.
- Global Surveillance for COVID-19 disease caused by human infection with novel coronavirus (COVID-19) Revised guidance 27 February 2020.
- World Health Organization, 2020. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected: interim guidance, January 2020 (No. WHO/2019-nCoV/IPC/v2020. 1). World Health Organization.
- World Health Organization, 2003. WHO hospital discharge and follow-up policy for patients who have been diagnosed with severe acute respiratory syndrome (SARS). *Geneva: The Organization*.
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 24 Jan 2020.
- Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China, CDC, 2020.
- SARS: Fact Sheet on Isolation and Quarantine, CDC, 2004.
- Specialist hospital Waibargi SOP for Wuhan Pneumonia
- Interim clinical guidance for patients suspected of/confirmed with covid-19 in belgium, 19 March 2020.
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial, Gautreta, et al., 2020.
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Yao et al., 2020.
- Informations for clinicians on therapeutic options for COVID-19 patients, CDC. March 21, 2020.
- Clinical Management Guidelines for COVID-19 disease Version 4, Yangon General Hospital, 2020.

- Papazian L, Aubron C, Brochard L, et al. (2019) Formal guidelines: management of acute respiratory distress syndrome, *Annals of Intensive Care*, 9:69.
- Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected (Interim guidance January 2020)WHO/2019nCoV/IPC/v2020.1
- COVID-19 Airway management principles (ICMANAESTHEAIACOVID-19.ORG)
- World Federation of Societies of Anaesthesiologists- Coronavirus- guidance for anaesthesia and perioperative care providers
- Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance, 20 March 2020.
- Discharge criteria for confirmed COVID-19 cases When is it safe to discharge COVID-19 cases from the hospital or end home isolation?, ECDC Technical Report
- Management Protocol for COVID-19 Acute Respiratory Disease in Yangon Children Hospital (Revised on 20-03-2020) (Version 04)
- Awake proning guide, MARY SEACOLE, Sandwell and West, Birmingham Hospitals, NHS Trust.